JAZZ
Price
$117.77
Change
+$1.10 (+0.94%)
Updated
Aug 15 closing price
Capitalization
7.14B
80 days until earnings call
SYRE
Price
$16.95
Change
+$0.09 (+0.53%)
Updated
Aug 15 closing price
Capitalization
1.02B
81 days until earnings call
Interact to see
Advertisement

JAZZ vs SYRE

Header iconJAZZ vs SYRE Comparison
Open Charts JAZZ vs SYREBanner chart's image
Jazz Pharmaceuticals
Price$117.77
Change+$1.10 (+0.94%)
Volume$490.61K
Capitalization7.14B
Spyre Therapeutics
Price$16.95
Change+$0.09 (+0.53%)
Volume$536.98K
Capitalization1.02B
JAZZ vs SYRE Comparison Chart in %
Loading...
JAZZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
JAZZ vs. SYRE commentary
Aug 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JAZZ is a Hold and SYRE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 17, 2025
Stock price -- (JAZZ: $117.77 vs. SYRE: $16.95)
Brand notoriety: JAZZ and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: JAZZ: 68% vs. SYRE: 90%
Market capitalization -- JAZZ: $7.14B vs. SYRE: $1.02B
JAZZ [@Biotechnology] is valued at $7.14B. SYRE’s [@Biotechnology] market capitalization is $1.02B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.71B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

JAZZ’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • JAZZ’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, JAZZ is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

JAZZ’s TA Score shows that 8 TA indicator(s) are bullish while SYRE’s TA Score has 6 bullish TA indicator(s).

  • JAZZ’s TA Score: 8 bullish, 2 bearish.
  • SYRE’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, JAZZ is a better buy in the short-term than SYRE.

Price Growth

JAZZ (@Biotechnology) experienced а +5.81% price change this week, while SYRE (@Biotechnology) price change was +11.22% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.94%. For the same industry, the average monthly price growth was +21.39%, and the average quarterly price growth was +21.23%.

Reported Earning Dates

JAZZ is expected to report earnings on Nov 05, 2025.

SYRE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+5.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
JAZZ($7.14B) has a higher market cap than SYRE($1.02B). JAZZ has higher P/E ratio than SYRE: JAZZ (15.38) vs SYRE (1.68). JAZZ YTD gains are higher at: -4.369 vs. SYRE (-27.191). JAZZ has higher annual earnings (EBITDA): 1.25B vs. SYRE (-214.36M). JAZZ has more cash in the bank: 2.57B vs. SYRE (565M). SYRE has less debt than JAZZ: SYRE (0) vs JAZZ (5.42B). JAZZ has higher revenues than SYRE: JAZZ (4.07B) vs SYRE (0).
JAZZSYREJAZZ / SYRE
Capitalization7.14B1.02B698%
EBITDA1.25B-214.36M-583%
Gain YTD-4.369-27.19116%
P/E Ratio15.381.68913%
Revenue4.07B0-
Total Cash2.57B565M455%
Total Debt5.42B0-
FUNDAMENTALS RATINGS
JAZZ vs SYRE: Fundamental Ratings
JAZZ
SYRE
OUTLOOK RATING
1..100
6710
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
73
Overvalued
PROFIT vs RISK RATING
1..100
88100
SMR RATING
1..100
6299
PRICE GROWTH RATING
1..100
5559
P/E GROWTH RATING
1..100
7684
SEASONALITY SCORE
1..100
7516

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SYRE's Valuation (73) in the Pharmaceuticals Major industry is in the same range as JAZZ (77) in the Pharmaceuticals Other industry. This means that SYRE’s stock grew similarly to JAZZ’s over the last 12 months.

JAZZ's Profit vs Risk Rating (88) in the Pharmaceuticals Other industry is in the same range as SYRE (100) in the Pharmaceuticals Major industry. This means that JAZZ’s stock grew similarly to SYRE’s over the last 12 months.

JAZZ's SMR Rating (62) in the Pharmaceuticals Other industry is somewhat better than the same rating for SYRE (99) in the Pharmaceuticals Major industry. This means that JAZZ’s stock grew somewhat faster than SYRE’s over the last 12 months.

JAZZ's Price Growth Rating (55) in the Pharmaceuticals Other industry is in the same range as SYRE (59) in the Pharmaceuticals Major industry. This means that JAZZ’s stock grew similarly to SYRE’s over the last 12 months.

JAZZ's P/E Growth Rating (76) in the Pharmaceuticals Other industry is in the same range as SYRE (84) in the Pharmaceuticals Major industry. This means that JAZZ’s stock grew similarly to SYRE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
JAZZSYRE
RSI
ODDS (%)
Bullish Trend 3 days ago
80%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
72%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
62%
Bullish Trend 3 days ago
85%
MACD
ODDS (%)
Bullish Trend 3 days ago
61%
Bullish Trend 3 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
62%
Bullish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
65%
Bullish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 5 days ago
60%
Bullish Trend 5 days ago
85%
Declines
ODDS (%)
Bearish Trend 7 days ago
56%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
70%
Bullish Trend 3 days ago
88%
Aroon
ODDS (%)
Bullish Trend 3 days ago
50%
Bullish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
JAZZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PCOTX19.18N/A
N/A
Victory Pioneer Core Equity C
FDLSX20.98-0.01
-0.05%
Fidelity Select Leisure
PMIVX11.03-0.01
-0.09%
Putnam Multi-Asset Income R6
MXVIX41.46-0.12
-0.29%
Empower S&P 500® Index Investor
LZSCX11.12-0.44
-3.81%
Lazard US Small Cap Equity Select Instl

JAZZ and

Correlation & Price change

A.I.dvisor indicates that over the last year, JAZZ has been loosely correlated with TECH. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if JAZZ jumps, then TECH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JAZZ
1D Price
Change %
JAZZ100%
+0.94%
TECH - JAZZ
42%
Loosely correlated
-0.26%
FTRE - JAZZ
41%
Loosely correlated
+1.77%
DAWN - JAZZ
38%
Loosely correlated
+8.00%
ROIV - JAZZ
37%
Loosely correlated
+0.85%
SYRE - JAZZ
36%
Loosely correlated
+0.53%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with IDYA. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
+0.53%
IDYA - SYRE
61%
Loosely correlated
-0.16%
CGON - SYRE
60%
Loosely correlated
-1.00%
BEAM - SYRE
59%
Loosely correlated
+1.08%
XNCR - SYRE
57%
Loosely correlated
+0.39%
CRNX - SYRE
55%
Loosely correlated
+3.47%
More